Five Things To Know When it Comes To iRECIST
Source: Premier Research
By Luke Gill

Evaluation of patient response to treatment of solid tumors is undergoing an important evolution under the new iRECIST guidance issued in early 2017. The RECIST 1.1 guideline remains the gold standard, but iRECIST is focusing attention on the future of tumor assessment methods.
Here are five things you should know about iRECIST as the standard shapes up as an important tool in assessing solid tumors.
VIEW THE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Clinical Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Premier Research
This website uses cookies to ensure you get the best experience on our website. Learn more